Court filing
Declaration — CHD v. FDA
Summary
Declaration of Suzann Burk in Support of Defendants' Motion to Dismiss, Document 18-1, filed 04/25/22 in Children's Health Defense, et al. v. Food & Drug Administration, et al., Case No. 6:22-cv-00093-ADA-DTG, in the United States District Court for the Western District of Texas, Waco Division. Burk states that she is the Director of the Division of Disclosure and Oversight Management at the FDA's Center for Biologics Evaluation and Research and is responsible for disclosing CBER documents in litigation. She attaches Exhibit 1, a Letter of Authorization to Pfizer Inc. dated Jan. 3, 2022 (reissuance), and Exhibit 2, a Fact Sheet for Recipients and Caregivers for Use in Individuals 5-11 years of age dated Jan. 3, 2022 (revised). She certifies that each was the current effective version as of January 24, 2022. The declaration is executed on April 21, 2022.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Filed April 25, 2022 in Children's Health Defense v. Food & Drug Administration; one of 15 filings from this case.
Record facts
| Court | U.S. District Court for the Western District of Texas, Waco Division |
|---|---|
| Filed | 2022-04-25 |
Cite this document
“Declaration — CHD v. FDA.”
U.S. District Court for the Western District of Texas, Waco Division, No. 6:22-cv-00093-ADA-DTG, Doc. 18-1, filed 2022-04-25. Archived at Pandemic Darlings, https://pandemicdarlings.com/court-filings/chd-v-fda/2022-04-25-burk-declaration/
, SHA-256 e4d977d428e41d1761e3df70ebd0dc2729fe609f97abf9acbbe568dd5bf5f4de.Full text
UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS WACO DIVISION Children’s Health Defense, et al., Plaintiffs, v. Food & Drug Administration, et al., Defendants. Case No. 6:22-cv-00093-ADA-DTG Declaration of Suzann Burk in Support of Defendants’ Motion to Dismiss I, Suzann Burk, declare as follows: 1. I am the Director of the Division of Disclosure and Oversight Management (“DDOM”), Office of Communication Outreach and Development, Center for Biologics Evaluation and Research (“CBER”), United States Food and Drug Administration (“FDA”), in Silver Spring, Maryland. 2. As the Director of DDOM, I have overall responsibility for the disclosure of documents officially maintained by CBER, the center in FDA that regulates biologic products such as blood, vaccines, gene therapy, and human cells, tissues, and cellular and tissue-based products. I have been the Director of DDOM since June 24, 2018. Prior to that date, I was the Team Lead of the Electronic Disclosure Team in DDOM for approximately nine and one-half years. Prior to that, I was a member of the Congressional and Oversight Branch in DDOM for two years and a member of the Access Litigation and Freedom of Information Branch in DDOM for four years. 3. In my capacity as Director of DDOM I have access to official CBER documents. I am responsible for disclosing documents in litigation on behalf of CBER. Case 6:22-cv-00093-ADA-DTG Document 18-1 Filed 04/25/22 Page 1 of 2 4. I submit this declaration in support of Defendants’ Motion to Dismiss Plaintiffs’ Complaint. The statements made in this declaration are based on my personal knowledge and official records available to me in my official capacity. 5. Attached hereto are copies of the following documents: Exhibit Document Date Exhibit 1 Letter of Authorization from Jacqueline A. O’Shaughnessy, Acting Chief Scientist, FDA, to Pfizer Inc. Jan. 3, 2022 (reissuance) Exhibit 2 Fact Sheet for Recipients and Caregivers for Use in Individuals 5–11 years of age Jan. 3, 2022 (revised) 6. I certify that each document listed in Paragraph 5 was the current effective version as of January 24, 2022, and was publicly available on FDA’s website, https://www.fda.gov, as of that date. 7. I declare under penalty of perjury that the foregoing Exhibits 1 and 2 and the facts contained in this declaration are true and correct pursuant to 28 U.S.C. § 1746. ________________________________ SUZANN BURK Division Director Office of Communication, Division of Disclosure and Oversight Management, Outreach and Development Center for Biologics Evaluation and Research Food and Drug Administration U.S. Department of Health and Human Services Executed on April 21, 2022 Suzann H. Burk -S Digitally signed by Suzann H. Burk -S Date: 2022.04.21 08:16:23 -04'00' Case 6:22-cv-00093-ADA-DTG Document 18-1 Filed 04/25/22 Page 2 of 2
File and source
- File
- gov.uscourts.txwd.1159970.18.1.pdf
- Size
- 107,650 bytes
- SHA-256
- e4d977d428e41d1761e3df70ebd0dc2729fe609f97abf9acbbe568dd5bf5f4de
- Original
- archive.org